Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
Saved in:
| Title: | Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. |
|---|---|
| Authors: | Brose MS; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA, United States., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Krajewska J; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Hoff AO; Department of Endocrinology, Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Vaisman F; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Hitre E; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States., Robinson B; Department of Medicine, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ngamphaiboon N; Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Guo X; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States., Simmons A; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States., Williamson D; Department of Biostatistics, Exelixis, Inc., Alameda, CA, United States., Andrianova S; Department of Late Phase Clinical Development, Exelixis, Inc., Alameda, CA, United States., Berry N; Department of Medical Affairs, Exelixis, Inc., Alameda, CA, United States., Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Mar 04; Vol. 16, pp. 1748566. Date of Electronic Publication: 2026 Mar 04 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1748566 |
